UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2022 or ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |----------------------------- ...

NASDAQ: CYTH cyclotherapeutics.com Corporate Presentation 2 Forward-Looking Statements Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in the public filings and other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |--------------------------- ...

NASDAQ: CYTH cyclotherapeutics.com Corporate Presentation 2 Forward-Looking Statements Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in the public filings and other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Nevada 59-3029743 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.0001 per share CYTH The Nasdaq Stock Market LLC Warrants to purchase Common Stock CYTHW The Nasdaq Stock Market LLC FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of ...

PART I: FINANCIAL INFORMATION [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements.) The company reported a significantly increased net loss of $11.5 million for the nine months ended September 30, 2021, driven by higher R&D and personnel costs Consolidated Balance Sheet Highlights (Unaudited) | Account | Sep 30, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $8,441,297 | $12,846,113 | | Total current assets | $10,992,175 | $14,050,237 | | Total Assets | $11,096,529 | $14,187,964 | | **Liabilities & Equity** | | | | Total current liabilities | $3,419,587 | $3,672,553 | | Total Liabilities | $3,469,475 | $3,735,482 | | Accumulated deficit | ($45,556,105) | ($34,061,836) | | Total stockholders' equity | $7,627,054 | $10,452,482 | Consolidated Statement of Operations Highlights (Unaudited) | Metric | Nine Months Ended Sep 30, 2021 | Nine Months Ended Sep 30, 2020 | | :--- | :--- | :--- | | Revenues | $1,000,641 | $757,790 | | Research and development | $7,739,379 | $4,859,794 | | Total operating expenses | $12,497,385 | $7,037,732 | | Loss from operations | ($11,496,744) | ($6,279,942) | | Net Loss | ($11,494,269) | ($6,261,993) | | Basic and Diluted Net Loss per Share | ($1.90) | ($4.34) | Consolidated Statement of Cash Flows Highlights (Unaudited) | Cash Flow Activity | Nine Months Ended Sep 30, 2021 | Nine Months Ended Sep 30, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | ($12,393,627) | ($5,478,838) | | Net cash provided by (used in) investing activities | $4,488 | ($27,259) | | Net cash provided by financing activities | $7,984,323 | $4,960,002 | | Net decrease in cash and cash equivalents | ($4,404,816) | ($546,095) | [Notes to Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements.) The notes detail the company's clinical focus, significant liquidity challenges, and recent capital-raising activities to fund operations - The company is a clinical-stage biotechnology company developing cyclodextrin-based products, with its lead candidate, Trappsol® Cyclo™, in a pivotal Phase III study for Niemann-Pick Type C (NPC) disease and a Phase II program planned for Alzheimer's disease[32](index=32&type=chunk)[34](index=34&type=chunk) - The company has incurred significant losses, with an **accumulated deficit of approximately $45.6 million** as of September 30, 2021, raising substantial doubt about the company's ability to continue as a going concern[71](index=71&type=chunk)[74](index=74&type=chunk) - For the nine months ended September 30, 2021, **four major customers accounted for 65% of total revenues**, indicating significant customer concentration[80](index=80&type=chunk) - Through September 30, 2021, the company raised **approximately $8.0 million in gross proceeds** from the exercise of warrants and established an Equity Distribution Agreement to potentially sell up to $20 million in common stock[95](index=95&type=chunk)[98](index=98&type=chunk)[100](index=100&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses rising operating expenses and net losses alongside clinical trial progress, highlighting the critical need for additional capital [Overview](index=19&type=section&id=Overview) The company is advancing its lead drug candidate, Trappsol® Cyclo™, through late-stage clinical trials for NPC and preparing for a Phase II study in Alzheimer's disease - The company's lead drug candidate is Trappsol® Cyclo™ for the treatment of Niemann-Pick Type C disease (NPC), a rare and fatal cholesterol metabolism disease[113](index=113&type=chunk) - In June 2021, the company commenced enrollment in **TransportNPC™, a pivotal Phase III study** of Trappsol® Cyclo™ for the treatment of NPC, with potential regulatory approval as early as 2023[117](index=117&type=chunk) - The company is also developing Trappsol® Cyclo™ for Alzheimer's disease and intends to submit an IND to the FDA for a **Phase II program in the second half of 2021**[120](index=120&type=chunk) [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Revenues grew 32% year-over-year for the nine-month period, but this was offset by significant increases in R&D, personnel, and professional fee expenses Revenue Comparison (Nine Months Ended Sep 30) | Period | 2021 | 2020 | Change | | :--- | :--- | :--- | :--- | | Total Revenues | $1,001,000 | $758,000 | +32% | Operating Expense Comparison (Nine Months Ended Sep 30) | Expense Category | 2021 | 2020 | Change | | :--- | :--- | :--- | :--- | | Personnel | $2,770,000 | $1,328,000 | +109% | | Research & Development | $7,739,000 | $4,860,000 | +59% | | Professional Fees | $1,047,000 | $435,000 | +141% | | Office and Other | $800,000 | $306,000 | +161% | - The increase in personnel expense was due to moving the CFO to full-time, executive bonus accruals, and non-cash compensation from stock option awards[135](index=135&type=chunk) - The increase in R&D expense is attributed to increased activity in the International Clinical Program and U.S. clinical trials, with **costs expected to rise further** with the Phase III trial[136](index=136&type=chunk) [Liquidity and Capital Resources](index=22&type=section&id=Liquidity%20and%20Capital%20Resources) The company's cash position has declined due to high operational cash burn for drug development, necessitating reliance on equity financing - **Cash decreased to $8.4 million** as of September 30, 2021, from $12.8 million at December 31, 2020, with cash used in operations at approximately $12.4 million for the nine months ended September 30, 2021[140](index=140&type=chunk) - Subsequent to its December 2020 Public Offering, the company received **gross proceeds of approximately $9.0 million** from the exercise of warrants through September 30, 2021[147](index=147&type=chunk) - The company will need to raise additional capital to support ongoing operations and clinical trials, which raises **substantial doubt about its ability to continue as a going concern**[149](index=149&type=chunk) [Critical Accounting Policies and Estimates](index=23&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) No significant changes were made to the company's critical accounting policies during the third quarter of 2021 - There were no significant changes to the company's critical accounting policies during the quarter ended September 30, 2021[155](index=155&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk.) This section is not applicable to the company for this reporting period - The company stated that this item is not applicable[157](index=157&type=chunk) [Item 4. Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded that the company's disclosure controls and procedures were effective with no material changes to internal controls - Based on an evaluation as of September 30, 2021, the principal executive officer and principal financial officer concluded that the **company's disclosure controls and procedures were effective**[159](index=159&type=chunk) - **No material changes** were made to the company's internal control over financial reporting during the last fiscal quarter[160](index=160&type=chunk) PART II: OTHER INFORMATION [Item 1A. Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors.) The company reports no new risk factors beyond those previously disclosed in its 2020 Annual Report on Form 10-K - No additional risk factors have been identified other than those included in the Annual Report on Form 10-K for the year ended December 31, 2020[163](index=163&type=chunk) [Item 6. Exhibits](index=25&type=section&id=Item%206.%20Exhibits.) This section lists all exhibits filed with the report, including officer certifications and Inline XBRL data files - The exhibits filed with this 10-Q include certifications by the CEO and CFO, and Inline XBRL documents[164](index=164&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |---------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2021 or ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |---------------------------- ...

Part I [Business](index=4&type=section&id=Item%201%2E%20Business) Cyclo Therapeutics develops Trappsol® Cyclo™ for Niemann-Pick Type C and Alzheimer's, while operating a legacy fine chemical business - The company's core focus is the development of **Trappsol® Cyclo™** for the rare and fatal disease Niemann-Pick Type C (NPC), with clinical programs underway in the U.S., Europe, and Israel[14](index=14&type=chunk)[15](index=15&type=chunk) - **Trappsol® Cyclo™** has received key regulatory designations, including Orphan Drug status in the U.S. and Europe, and Fast Track designation from the FDA, potentially accelerating its path to market[18](index=18&type=chunk) - The company is also exploring **Trappsol® Cyclo™** for Alzheimer's disease, with a single-patient expanded access program showing disease stabilization and plans to engage the FDA on a clinical trial protocol in early 2021[20](index=20&type=chunk)[49](index=49&type=chunk) - The estimated total addressable annual market for treating NPC with **Trappsol® Cyclo™** is approximately **$550 million**[24](index=24&type=chunk) Research and Development Expenses (2019-2020) | Year | R&D Expense (Approx.) | | :--- | :--- | | 2020 | $6,096,000 | | 2019 | $4,869,000 | [Clinical Studies for NPC](index=6&type=section&id=Clinical%20Studies%20for%20NPC) Trappsol® Cyclo™ clinical studies for NPC show promising safety and efficacy, with 86% of patients meeting the primary endpoint in the European/Israeli Phase I/II trial - In the European/Israeli Phase I/II study, **6 out of 7 patients (86%)** who completed the trial met the efficacy endpoint of at least a one-point improvement in two or more of the 17 domains on the NPC Clinical Severity Scale[34](index=34&type=chunk)[35](index=35&type=chunk) - Data from the U.S. Phase I study demonstrated that **Trappsol® Cyclo™** removes trapped cholesterol from liver cells and reduces levels of the protein tau in a majority of patients, suggesting it prevents neurodegeneration[40](index=40&type=chunk)[41](index=41&type=chunk)[44](index=44&type=chunk) - Based on clinical data, the company has selected the **2000 mg/kg dose** for its pivotal Phase III trial and received a "Study May Proceed" notification from the FDA in October 2020[16](index=16&type=chunk)[38](index=38&type=chunk) [Government Regulation](index=12&type=section&id=Government%20Regulation) The company's biopharmaceutical products are subject to extensive FDA regulation, benefiting from Orphan Drug and Fast Track designations to expedite approval - The FDA drug approval process is lengthy and complex, generally involving preclinical studies, an IND application, Phase I-III clinical trials, and submission of an NDA[57](index=57&type=chunk)[58](index=58&type=chunk)[71](index=71&type=chunk) - **Trappsol® Cyclo™** has been granted Orphan Drug Designation by the FDA, which provides a **seven-year period of marketing exclusivity** for the treatment of NPC upon approval[89](index=89&type=chunk)[90](index=90&type=chunk) - The company received Fast Track Designation for **Trappsol® Cyclo™** in January 2017, which is intended to expedite the development and review of drugs for serious conditions with unmet medical needs[93](index=93&type=chunk)[94](index=94&type=chunk) - NPC was designated a Rare Pediatric Disease by the FDA, making the company eligible for a **priority review voucher** upon market approval, which can be used to shorten a future FDA review time or be sold to another company[100](index=100&type=chunk) [Legacy Fine Chemical Business](index=20&type=section&id=Legacy%20Fine%20Chemical%20Business) The legacy fine chemical business, generating most revenue from cyclodextrin sales, faces significant customer concentration and relies on major manufacturers for supply - In 2020, revenues were composed of **3% biopharmaceuticals**, **96% basic cyclodextrins**, and **1% cyclodextrin complexes**[119](index=119&type=chunk) - The business has significant customer concentration, with **three customers accounting for 69% of sales in 2020** and four customers accounting for 70% in 2019[121](index=121&type=chunk) [Risk Factors](index=23&type=section&id=Item%201A%2E%20Risk%20Factors) The company faces significant risks including financial losses, capital needs, single product dependency, clinical trial failures, and customer concentration in its legacy business - The company has a history of net losses, reporting approximately **$8.9 million** in 2020 and **$7.5 million** in 2019, and will require additional capital to fund its clinical trials and operations[126](index=126&type=chunk)[127](index=127&type=chunk) - The company is largely dependent on the success of its lead drug candidate, **Trappsol® Cyclo™**, which may never receive regulatory approval or achieve market acceptance[132](index=132&type=chunk)[134](index=134&type=chunk) - The company relies on unpatented trade secrets to protect its manufacturing process for **Trappsol® Cyclo™**, which are difficult to protect and may not provide a competitive advantage if discovered by others[154](index=154&type=chunk)[155](index=155&type=chunk) - A small number of customers account for a substantial portion of the legacy fine chemical business revenue, with the **top five customers representing 81% of total sales in fiscal 2020**[184](index=184&type=chunk)[185](index=185&type=chunk) - The recent COVID-19 pandemic poses a risk of disruption to clinical trials, supply chain, and the ability to raise capital[152](index=152&type=chunk) [Unresolved Staff Comments](index=34&type=section&id=Item%201B%2E%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments [Properties](index=34&type=section&id=Item%202%2E%20Properties) The company leases its principal office and warehouse space in Gainesville, Florida, under an agreement expiring in January 2023 - The company leases its principal office and warehouse space in Gainesville, Florida. The current lease expires on **January 31, 2023**[199](index=199&type=chunk) [Legal Proceedings](index=34&type=section&id=Item%203%2E%20Legal%20Proceedings) The company is not currently involved in any material litigation - The company reports that it is not currently involved in any litigation that would have a material adverse effect on its financial position or results of operations[200](index=200&type=chunk) [Mine Safety Disclosures](index=34&type=section&id=Item%204%2E%20Mine%20Safety%20Disclosures) Not applicable Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=35&type=section&id=Item%205%2E%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock and warrants trade on Nasdaq, with no dividends paid or anticipated, as earnings are retained for business expansion - Common Stock and warrants are traded on the Nasdaq Capital Market under symbols "**CYTH**" and "**CYTHW**"[205](index=205&type=chunk) - The company has never paid cash dividends and does not anticipate paying any in 2021, intending to retain earnings for business expansion[207](index=207&type=chunk) [Selected Financial Data](index=35&type=section&id=Item%206%2E%20Selected%20Financial%20Data) Not applicable [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=36&type=section&id=Item%207%2E%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Net loss increased in 2020 due to higher R&D and personnel costs, despite improved liquidity from capital raises, with additional funding required for future clinical development Key Financial Results (2020 vs. 2019) | Metric | 2020 | 2019 | | :--- | :--- | :--- | | Total Revenues | $903,000 | $1,007,000 | | R&D Expenses | $6,096,000 | $4,869,000 | | Personnel Expenses | $2,562,000 | $1,906,000 | | Net Loss | ($8,942,000) | ($7,532,500) | Liquidity Position (End of Year) | Metric | Dec 31, 2020 | Dec 31, 2019 | | :--- | :--- | :--- | | Cash | $12,846,000 | $2,784,000 | | Cash Used in Operations | ($8,540,000) | ($6,589,000) | - In December 2020, the company raised gross proceeds of **$14.375 million** in a public offering. This, along with other private placements, significantly strengthened its cash position[241](index=241&type=chunk)[242](index=242&type=chunk) - The company believes it has sufficient cash to meet operating costs and capital requirements through March 2022, but will need to raise additional capital to continue its clinical trials and fund ongoing operations beyond that[245](index=245&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%207A%2E%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Not applicable [Financial Statements and Supplementary Data](index=42&type=section&id=Item%208%2E%20Financial%20Statements%20and%20Supplementary%20Data) This section presents audited consolidated financial statements for 2020 and 2019, including notes and the auditor's report highlighting going concern and inventory valuation Consolidated Balance Sheet Data (as of Dec 31) | Metric | 2020 | 2019 | | :--- | :--- | :--- | | Cash and cash equivalents | $12,846,113 | $2,783,719 | | Total Assets | $14,187,964 | $4,113,228 | | Total Liabilities | $3,735,482 | $3,177,246 | | Total Stockholders' Equity | $10,452,482 | $935,982 | Consolidated Statement of Operations Data (Year Ended Dec 31) | Metric | 2020 | 2019 | | :--- | :--- | :--- | | Product Sales | $903,376 | $1,007,198 | | Research and Development | $6,096,445 | $4,869,160 | | Loss from Operations | ($8,961,405) | ($7,544,560) | | Net Loss | ($8,941,603) | ($7,532,533) | | Basic and Diluted Net Loss per Share | ($5.60) | ($6.97) | - The independent auditor's report identified the company's business plan and going concern considerations, as well as the valuation of inventory, as critical audit matters[270](index=270&type=chunk)[272](index=272&type=chunk)[276](index=276&type=chunk) [Notes to Consolidated Financial Statements](index=50&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Notes detail revenue breakdown, significant customer concentration, equity transactions including a reverse stock split and capital raises, and net operating loss carryforwards - In 2020, **three major customers accounted for 69% of total revenues**, and their balances represented 74% of total accounts receivable at year-end[338](index=338&type=chunk) - On December 8, 2020, the company effected a **1-for-100 reverse stock split** of its common stock[358](index=358&type=chunk) - The company has approximately **$25.2 million** in federal and state net operating loss carryforwards available to offset future taxable income, though a 100% valuation allowance has been applied[375](index=375&type=chunk)[377](index=377&type=chunk) - In May 2020, a subsidiary borrowed **$158,524** under the Paycheck Protection Program (PPP), which may be forgiven if qualifying expenses are met[356](index=356&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=63&type=section&id=Item%209%2E%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) None reported [Controls and Procedures](index=63&type=section&id=Item%209A%2E%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2020, with no material changes reported - Based on an evaluation, management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of **December 31, 2020**[404](index=404&type=chunk) - Management's assessment concluded that the company's internal control over financial reporting was effective as of **December 31, 2020**, based on the COSO framework[407](index=407&type=chunk) [Other Information](index=64&type=section&id=Item%209B%2E%20Other%20Information) None Part III [Directors, Executive Officers and Corporate Governance](index=65&type=section&id=Item%2010%2E%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the 2021 Proxy Statement - This information will be filed in the Proxy Statement for the 2021 Annual Meeting of Stockholders within 120 days of the fiscal year-end[412](index=412&type=chunk) [Executive Compensation](index=65&type=section&id=Item%2011%2E%20Executive%20Compensation) Executive compensation information is incorporated by reference from the 2021 Proxy Statement - This information will be filed in the Proxy Statement for the 2021 Annual Meeting of Stockholders[413](index=413&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=65&type=section&id=Item%2012%2E%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Security ownership information is incorporated by reference from the 2021 Proxy Statement - This information will be filed in the Proxy Statement for the 2021 Annual Meeting of Stockholders[414](index=414&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=65&type=section&id=Item%2013%2E%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Related party transactions and director independence information is incorporated by reference from the 2021 Proxy Statement - This information will be filed in the Proxy Statement for the 2021 Annual Meeting of Stockholders[415](index=415&type=chunk) [Principal Accountant Fees and Services](index=65&type=section&id=Item%2014%2E%20Principal%20Accountant%20Fees%20and%20Services) Principal accountant fees and services information is incorporated by reference from the 2021 Proxy Statement - This information will be filed in the Proxy Statement for the 2021 Annual Meeting of Stockholders[416](index=416&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=66&type=section&id=Item%2015%2E%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists exhibits filed with the Form 10-K, including corporate documents, material contracts, and officer certifications

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |----------------------- ...